Ashley Bedi, DO
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
- Since medical school
- 8 years
- Des Moines University of Osteopathic Medicine and Health Sciences, 2018
Offices
3 locations · Adventist Health Physicians Network · 628 clinicians in this group
Hospitals listed: Adventist Health Lodi Memorial. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bedi’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health Lodi MemorialLodi, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.222, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Health Lodi Memorial
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 6 the same, 0 worse of 6 measures. Readmissions: 1 better, 3 the same, 2 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.222 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.19 (0.16 to 2.22) · 678 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.59 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 203.28 (143.15 to 263.4) · 29 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 43 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 334 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.2 · 570 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.9 · 184 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.1 · 1,823 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.02 to 0.45) · 4,072 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.08 to 0.49) · 4,094 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.18 (0.83 to 5.53) · 476 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.63 (0 to 3.34) · 81 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.8 to 4.13) · 448 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.29 (0 to 17.86) · 79 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 78 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.18 to 3.16) · 142 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.74 (0 to 1.53) · 3,347 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.368 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.655 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.506 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 27 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 450 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 47.3 · 381 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.2 · 604 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 20.1 · 661 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.9 · 188 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.6 (8.9 to 15.2) · 932 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 449 cases | No different | Jan 2024 – Dec 2024 |
What patients said (438 patients answered, 17% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 70% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$33,233
Medicare paid this office $33,233 for 208 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 64 | $5,710 | $58 |
| Long return visit (40+ min) | 26 | $2,873 | $96 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 14 | $2,716 | $80 |
| New patient visit (60+ min) | 25 | $2,590 | $104 |
| Muscle electrical test | 28 | $2,453 | $63 |
See all 13 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 64 | $5,710 | $58 |
| Long return visit (40+ min) | 26 | $2,873 | $96 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 14 | $2,716 | $80 |
| New patient visit (60+ min) | 25 | $2,590 | $104 |
| Muscle electrical test | 28 | $2,453 | $63 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 18 | $2,342 | $76 |
| Nerve test | 12 | $2,000 | $167 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,536 | $96 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | 13 | $1,529 | $46 |
| Return visit (30+ min) | 20 | $1,515 | $63 |
| Short return visit (20+ min) | 19 | $926 | $46 |
| Ultrasonic guidance for needle placement | 18 | $673 | $22 |
| Muscle electrical test | 15 | $521 | $14 |
Procedures year by year
| Procedure | 2022 | 2023 | 2024 |
|---|---|---|---|
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | – | 27 | 34 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | – | 29 | 31 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | – | 20 | 33 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
208 Original Medicare patients in 2024. Average age 67 · Under 65 29% · 85 and older 8% · Women 49% · Also on Medicaid 33% · Health risk score 1.95. Above the middle of the specialty; the typical physical medicine and rehabilitation clinician is at 1.53.
Conditions among them: High blood pressure 63% · Depression 41% · Chronic kidney disease 28% · Diabetes 27% · Coronary heart disease 25% · Stroke 25% · Heart failure 24% · COPD 17% · Atrial fibrillation 17% · Dementia 15% · Cancer 12%.
The office billed $364,521, Medicare allowed $44,506 and paid $33,233; for 540 services of 39 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 208 | 540 | 67 | 1.95 | $364,521 | $33,233 |
| 2023 | 227 | 616 | 69 | 1.85 | $361,474 | $40,177 |
| 2022 | 87 | 194 | 67 | 2.13 | $88,473 | $12,547 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 86 | $9,817 | $59 |
| Long return visit (40+ min) | 45 | $6,434 | $102 |
| New patient visit (60+ min) | 22 | $2,695 | $123 |
| Muscle electrical test | 26 | $2,513 | $74 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 5 or more muscles, first extremity | 12 | $2,229 | $83 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $1,938 | $97 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 18 | $1,889 | $65 |
| Nerve test | 11 | $1,462 | $133 |
| Return visit (30+ min) | 16 | $1,296 | $68 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, each additional extremity | 14 | $953 | $48 |
| Ultrasonic guidance for needle placement | 17 | $803 | $21 |
| Short return visit (20+ min) | 12 | $493 | $41 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 11 | $397 | $23 |
| Muscle electrical test | 13 | $294 | $13 |
2022: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 42 | $4,513 | $53 |
| New patient visit (60+ min) | 13 | $1,780 | $137 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,403 | $100 |
Medicaid work
$2,107 in 2024
Medicaid paid $2,107 for 53 billed services this clinician did in 2024, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Chemodenervation of one extremity; 1-4 muscle(s) | 29 | $1,441 |
| Chemodenervation of one extremity; each additional extremity, 1-4 muscle(s) (List separately in addition to code for primary procedure) | 12 | $499 |
| Needle electromyography for guidance in conjunction with chemodenervation (List separately in addition to code for primary procedure) | 12 | $167 |
| 2024 | 53 | 3 | 16 | $2,107 |
Drugs they prescribed that Part D paid
$9,182
Pharmacies billed $9,182 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 8% of their Part D prescriptions (20 of 239) in 2024. At or below the middle of the specialty; the typical physical medicine and rehabilitation clinician is at 12%.
233 generic and fewer than 11 brand-name prescriptions · $9,182 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Baclofen | 100 | $2,762 | $28 |
| Dantrolene | 14 | $1,586 | $113 |
| Tizanidine | 35 | $424 | $12 |
| Gabapentin | 21 | $371 | $18 |
| Cyclobenzaprine | 13 | $125 | $10 |
See all 6 drugs
| Baclofen | 100 | $2,762 | $28 |
| Dantrolene | 14 | $1,586 | $113 |
| Tizanidine | 35 | $424 | $12 |
| Gabapentin | 21 | $371 | $18 |
| Cyclobenzaprine | 13 | $125 | $10 |
| Pregabalin | 13 | $68 | $5 |
Year by year
| 2024 | 239 | 56 | 8% (20) | None | $9,182 |
| 2023 | 234 | 48 | 7% (17) | None | $7,491 |
| 2022 | 12 | None | None | None | $1,753 |
| 2019 | 79 | 26 | None | None | $1,587 |
| 2018 | 33 | 18 | None | None | $441 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Baclofen | 90 | $2,492 | $28 |
| Dantrolene | 18 | $2,449 | $136 |
| Tizanidine | 31 | $464 | $15 |
| Gabapentin | 33 | $442 | $13 |
| Pregabalin | 14 | $140 | $10 |
| Cyclobenzaprine | 13 | $135 | $10 |
Money from drug and device companies
$982 in 2025
A payment is not proof that care is biased.
| Ucb | Nayzilam | $160 | 5 payments
|
| Merz Pharmaceuticals | Inbrija | $147 | 2 payments
|
| Abbvie | Qulipta | $141 | 7 payments
|
| LivaNova USA | Vns Therapy Sentiva Model 1000 Generator | $68 | 1 payment
|
| Janssen Biotech | None | $60 | 2 payments
|
| Argenx US | Vyvgart Hytrulo | $57 | 2 payments
|
See all 35 published payments
| Tanabe Pharma America | Meals · 2025-12-18 | Radicava | $30 |
| Abbvie | Meals · 2025-12-17 | Qulipta | $21 |
| LivaNova USA | Meals · 2025-12-17 | Vns Therapy Sentiva Model 1000 Generator | $68 |
| Otsuka America Pharmaceutical | Meals · 2025-12-09 | Rexulti | $21 |
| Janssen Biotech | Meals · 2025-12-08 | None | $26 |
| Biogen | Meals · 2025-12-08 | Leqembi | $24 |
| Merz Pharmaceuticals | Meals · 2025-12-04 | Inbrija | $125 |
| Ucb | Meals · 2025-12-02 | Nayzilam | $48 |
| Abbvie | Meals · 2025-11-18 | Qulipta | $21 |
| Abbvie | Meals · 2025-11-17 | Vyalev | $12 |
| MicroTransponder | Meals · 2025-11-04 | None | $14 |
| Genentech USA | Meals · 2025-10-06 | Ocrevus Zunovo | $17 |
| Argenx US | Meals · 2025-10-01 | Vyvgart Hytrulo | $33 |
| Janssen Biotech | Meals · 2025-09-29 | None | $34 |
| ANI Pharmaceuticals | Meals · 2025-09-24 | Purified Cortrophin Gel | $26 |
| Otsuka America Pharmaceutical | Meals · 2025-09-23 | Rexulti | $30 |
| Abbvie | Meals · 2025-09-16 | Qulipta | $28 |
| Amneal Pharmaceuticals | Meals · 2025-09-16 | Ongentys | $14 |
| Azurity Pharmaceuticals | Meals · 2025-09-12 | Zonisade | $21 |
| Eisai | Meals · 2025-09-11 | Leqembi | $19 |
| Alexion Pharmaceuticals | Meals · 2025-08-21 | Ultomiris | $14 |
| Abbvie | Meals · 2025-08-18 | Qulipta | $18 |
| Lilly USA | Meals · 2025-08-14 | Kisunla | $22 |
| Biogen | Meals · 2025-08-12 | Tysabri | $17 |
| Argenx US | Meals · 2025-08-11 | Vyvgart Hytrulo | $24 |
| Ucb | Meals · 2025-08-01 | Nayzilam | $42 |
| Eisai | Meals · 2025-07-25 | Leqembi | $22 |
| Abbvie | Meals · 2025-07-22 | Qulipta | $17 |
| Merz Pharmaceuticals | Meals · 2025-07-03 | Xeomin | $22 |
| Abbvie | Meals · 2025-06-25 | Qulipta | $24 |
| Amneal Pharmaceuticals | Meals · 2025-06-09 | Rytary | $29 |
| Ucb | Meals · 2025-06-05 | Fintepla | $1 |
| Ucb | Meals · 2025-06-05 | Fintepla | $22 |
| Lundbeck | Meals · 2025-06-04 | Rexulti | $27 |
| Ucb | Meals · 2025-05-07 | Zilbrysq | $47 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 77.4 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1770076994
- Licence
- WI 73762-21
- Trained
- Des Moines University of Osteopathic Medicine and Health Sciences, 2018 · 8 years ago
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 208100000X (208100000X)
- Mailing address
- 515 S Fairmont Ave, Lodi, CA, 95240
- NPI first listed
- 2018-06-12
- NPI last updated
- 2025-07-29
- NPI record certified
- 2025-07-29
This is when the NPI record was last certified, not a medical board exam.